Category: Creating Tomorrow

Update: In early 2023, Dr. Thébaud’s team treated the first baby in their clinical trial that aims to prevent BPD in premature infants. This is the first trial of its kind in in the world. Read Dr. Thébaud’s Q&A to learn more about his critical work and what motivates him.

Published: August 2020

Little Olivia Eberts had oxygen tubes in her nose until after her first birthday. Because she was born prematurely, her tiny lungs were underdeveloped, and she couldn’t breathe without oxygen. Ironically for Olivia, and many premature babies like her, the oxygen that saved her life also damaged her lungs, causing bronchopulmonary dysplasia (BPD), which is like starting out life with emphysema. But a clinical trial at The Ottawa Hospital led by Dr. Bernard Thébaud, which uses stem cells to heal the lungs of premature babies, may be a game changer.

An unexpected early birth

Jamie Eberts was 22 weeks pregnant with twins when she started feeling some discomfort. She arrived at the General Campus of The Ottawa Hospital and was admitted — she was going into early labour.

Thankfully, the doctors and nurses at The Ottawa Hospital were ready for any scenario Jamie, her husband Tim, and the babies faced. Each day, there were gentle conversations about how the babies were doing, the process of delivering them, and the chances of survival. Every hour counted. Then, one of the babies developed an infection and all three lives were at risk — the babies had to be delivered.

Baby in NICU
Baby Olivia in the neonatal intensive care unit (NICU).

“Our babies, Liam and Olivia, were born at 5 a.m. on January 29, 2017, at 23-and-half-week’s gestation. Liam was born first. He was small, red, and didn’t make a sound,” remembers Jamie. Olivia weighed one pound, two ounces and Liam weighed only a few ounces more than she did. Both babies required oxygen and mechanical ventilation to keep them alive. As a result, both developed BPD — the most common cause of death in premature babies.

Sadly, baby Liam passed away a few weeks after he was born while Olivia remained in the Neonatal Intensive Care Unit (NICU) at The Ottawa Hospital for nine long months.

BPD in Canada

Jamie Eberts carrying baby Olivia.

In Canada, 1,000 babies are diagnosed with BPD every year. Often, babies with BPD develop other chronic lung diseases, such as asthma, and many require prolonged oxygen and ventilation. Additionally, they have a high incidence of hospital readmissions in the first two years of life. Babies with BPD often have problems in other organs as well, such as the brain or the eyes.

When Olivia was finally discharged, she went home with an oxygen tank. During the first year of her life, Olivia spent more time in hospital than out.

“Even now, a simple flu that put me in bed for a couple of days put her in hospital and turns into pneumonia. It’s scary,” says Jamie. The doctor told her that with Olivia’s respiratory issues, she may require hospital intervention for the rest of her life.

Lack of treatment options

“Currently there is no treatment for this disease,” says Dr. Bernard Thébaud, a neonatologist and senior scientist at The Ottawa Hospital. With that being said, he’s determined to improve the outcome for babies, like Olivia, who have BPD.

 “In the laboratory, we discovered that a particular type of stem cell can prevent BPD or regenerate newborn lungs.”

— Dr. Bernard Thébaud
Read our Q&A with Dr. Bernard Thébaud
Dr. Bernard Thebaud, neonatal intensive care unit, The Ottawa Hospital
Dr. Bernard Thebaud in the neonatal intensive care unit (NICU) at The Ottawa Hospital.

“Our research uses stem cells, isolated from the umbilical cords of healthy newborns, to prevent the lung injury or even to some degree regenerate a damaged lung in the laboratory. We foresee that these stem cells, given during a certain time during the hospital stay of these babies, could prevent the progression of the lung disease.”

Unlike traditional stem cells that can directly replace damaged cells and tissues, the stem cells that Dr. Thébaud is studying work by producing healing factors that promote regeneration and repair.

Clinical trial offers hope

Dr. Thébaud and his research team have launched a phase I clinical trial to test the feasibility and safety of the stem cell treatment in premature babies. The team is doing everything in their power to make this clinical trial a success, including consulting with healthcare providers and parents of premature babies.

One thing they’ve learned from these consultations is that many parents don’t feel like they know enough about stem cells and clinical trials to decide if they want to enroll their child in the trial. So, Dr. Thébaud and his team created an animated video to explain these concepts and help parents make an informed decision. Parents can share the video with family members if they’d like a second opinion.

Jamie was involved in these consultations and her firsthand experience provided valuable insight to the research team as they planned this project. This is just one example of how researchers at The Ottawa Hospital are partnering with patients and caregivers to improve the quality and success of their research.

Dr. Bernard Thébaud looks at a premature baby in an isolette.
Dr. Bernard Thébaud looks at a premature baby in an isolette.

Dr. Thébaud and his team held a “dress rehearsal” for the clinical trial. “The dress rehearsal lets us test and tweak our tools for approaching parents, including the video, so we know what works best once we’re ready to begin offering the experimental treatment.”

If this initial trial is successful, Dr. Thébaud and his team will launch a larger Canadian clinical trial. “This is a critical step towards providing a potential breakthrough therapy that could help premature babies in Canada and around the world,” says Dr. Thébaud.

The made-in-Ottawa clinical trial is supported by The Ottawa Hospital’s Ottawa Methods Centre and Biotherapeutics Manufacturing Centre, and the Blueprint Translational Research Group.

First trial of its kind in Canada

“Stem cell research is incredibly innovative. Here, we have a very promising, emerging therapy that could prevent lung injury but also improve brain development and eyesight,” says Janet Brintnell, Clinical Manager of the NICU who has seen dozens of premature babies with BPD.

“It’s amazing when you think of what it may be able to do for the quality of life for the child, for their family, and for our healthcare system. It could reduce length of stay, hospital admissions, and improve long-term outcomes. It could help these little ones lead healthier lives.”

— Janet Brintnell

“We are the only ones doing this kind of stem cell research in Canada, and there are only a few other teams in the world that are doing this.”

— Dr. Bernard Thébaud

Yet, three years ago when Olivia was in the NICU, this treatment wasn’t yet available. Now, Jamie and Tim are self-described “cheerleaders” of Dr. Thébaud’s research and are hopeful for what it might mean for future preemies and their families.

“I believe this is our future,” says Jamie. “When I think about what this could have done for our family, I wonder if Liam could have possibly survived. Olivia may not be facing the delays she’s experiencing today. Even to this day, if we are asked to put Olivia in the trial as an older candidate, we will.”

Jamie also adds the there was an impact from a mental health and financial perspective. “Our oldest child, Jacob, has had a very unusual first four years of his life because of how adaptable he has had to be during these difficult times. As a family, this entire experience has been very challenging financially due to a variety of therapies for Olivia and having to get used to becoming a single income family for several years in order to manage Olivia’s complicated schedule. All of this could have potentially been avoided if Dr. Thébaud’s research were available to our twins.”

A new beginning

Olivia is now a happy, active toddler who loves copying what her older brother Jacob does. Although, she still has BPD, it is increasingly manageable, and she no longer requires supplemental oxygen. While Olivia may suffer respiratory illness her entire life, one day a stem cell treatment developed here in Ottawa could mean that the next generation of babies with BPD won’t.

Jamie Eberts with her daughter, Olivia
Jamie Eberts with her daughter, Olivia.

Listen to Pulse Podcast and learn how one day stem cells could heal the lungs of premature babies with Dr. Bernard Thébaud and what it could mean for parents like Jamie Eberts.

The Ottawa Hospital is a leading academic health, research, and learning hospital proudly affiliated with the University of Ottawa.

Categories: Biotherapeutics, Creating Tomorrow, NICU, Stem Cell

Immunotherapy provides a second chance after dire lung cancer diagnosis

As a lawyer, Andrea Redway has worked on international initiatives relating to justice reform. She’s travelled the world tackling big projects and has always been ready to face new challenges head-on—but nothing could have prepared Andrea for a stage 4 lung cancer diagnosis. This diagnosis rocked her world and left her wondering how long she would survive.

The first signs of trouble appeared in January 2015 when Andrea developed a cough that persisted. In March, she left on a work trip abroad. It was an exciting career opportunity with the added bonus of being able to bring her husband and two children, who were 8 and 11 at the time. Three weeks after returning home, the cough continued and she couldn’t shake her jet lag. “Usually I’m over jet lag in a week. I was still so exhausted, and thought maybe I had pneumonia,” recalls Andrea.

“Here I was, 47 years old and I had no risk factors. I would never have thought that I could get lung cancer.” – Andrea Redway

Grim diagnosis

With no family doctor, she went to a walk-in clinic and was prescribed antibiotics. Within a few days, she started noticing other symptoms. “I had strange pains in my leg and then some cramping in my abdomen. The exhaustion continued.”

Andrea received a referral to a family doctor and an x-ray was ordered. The results showed a large mass on her lung. Within a week, she received the grim diagnosis—stage 4 lung cancer. The cancer had already spread to her bones, adrenal glands, brain and there were early signs of it in her colon. She was shocked beyond belief. “Here I was, 47 years old and I had no risk factors. I would never have thought that I could get lung cancer.”

Andrea Redway and family
Andrea, husband Michael Cayley, with their two children in Tofino, B.C. post diagnosis.

All Andrea and her husband could think about was getting on treatment right away. She had to, for the sake of her children.

She was referred to Dr. Garth Nicholas, an oncologist at The Ottawa Hospital and began chemotherapy treatment along with a small amount of radiation. Six weeks later, a scan revealed the chemotherapy was only partially working.

Clinging to life

Dr. Garth Nicholas at The Ottawa Hospital
Dr. Garth Nicholas is an oncologist at The Ottawa Hospital

Dr. Nicholas was aware of a new clinical trial, published in the New England Journal of Medicine. It was an immunotherapy treatment specifically used to treat stage 4 lung cancer, but it wasn’t yet available in Canada. He applied for the compassionate care program with the drug company and Andrea was given one dose of the drug, Nivolumab. Today, Nivolumab is now routinely used to treat many people with lung cancer. It is also used to treat other cancers, most notably melanoma.

But Andrea’s cancer continued to progress and she became very sick. Back in hospital, it was discovered that she had a perforated bowel. She recalls the situation being dire, “I needed emergency surgery or that was going to be the end of the line for me.”

Given the progression of Andrea’s cancer, it was uncertain if surgery was a viable option, but her care team at The Ottawa Hospital wanted to give Andrea the chance to have more time with her family. “Dr. Guillaume Martel, who is my saviour, did the surgery. Here I am today as a result,” says Andrea.

Once she recovered from surgery, Andrea was able to resume treatment to take on the cancer, which had ravaged her body. One month later, she received her second dose of immunotherapy. “I continued with immunotherapy for about two years. I completed my treatment in September 2017 and I’ve been great ever since.”

“Everything else is gone. It’s amazing—totally amazing. With little kids, we’ve had so many special moments since then.” – Andrea Redway

Eight months after starting treatment, Andrea’s scan showed the cancer was gone from outside of her lungs and the primary tumour on her lung had shrunk to about half. “When the tumour showed up on the scan originally, it was six centimeters. Now, it’s about 2.5 centimeters. It’s been described as mostly necrotic or dead.”

Transformational results

While Andrea did experience side effects like fatigue, dry eyes and joint pain, she says it was a small price to pay because immunotherapy was a game changer. “Everything else is gone. It’s amazing—totally amazing. With little kids, we’ve had so many special moments since then.”

Dr. Nicholas explains how much cancer treatment has improved in just four years since Andrea’s initial diagnosis. “Immunotherapy has become a standard part of the treatment of lung cancer over the past four years or so. There are rare patients like Andrea for whom it is an extraordinarily effective treatment, much better than any other therapy we’ve had in the past.”

However, Dr. Nicholas adds that not every lung cancer patient has a positive response like Andrea, and more research needs to be done. “There is a lot of ongoing research into why some tumours respond to immunotherapy while others do not, and whether we can do anything to alter non-responding tumours in order to make them respond.”

Today, Andrea continues to embrace those special moments, grateful to be watching her children grow.

The Ottawa Hospital is a leading academic health, research, and learning hospital proudly affiliated with the University of Ottawa.

Categories: Immunotherapy, Immunotherapy

Could cancer biotherapeutics be the next revolution in cancer treatment?

From helping the body’s own immune system better detect and fight cancer, to treating cancer with genetically-enhanced immune cells, viruses and vaccines, The Ottawa Hospital is conducting cutting-edge research that could transform cancer care right here at home and around the world.

For decades, scientists have tried to stimulate the immune system to attack cancer cells. A breakthrough came through the discovery that cancer cells make key molecules that suppress immune cells and prevent them from attacking the cancer. This discovery opened the door to revolutionary immunotherapy drugs called checkpoint inhibitors, which have shown striking results in recent years.

While promising research on checkpoint inhibitors continues, the race is now on to bring an innovative new kind of immunotherapy to patients – one that uses living cells, viruses and genes to fight cancer.

The Ottawa Hospital is a world leader in developing these innovative therapies, called cancer biotherapeutics.

“Our immune system is constantly trying to recognize and kill cancer cells, but the cancer cells are always trying to hide from it.”

— Dr. John Bell

Helping the body recognize and destroy cancer

CAR T-cell therapy is an emerging biotherapeutic treatment that harnesses the power of a patient’s own immune cells, known as T-cells, to treat their cancer. T-cells play a critical role in the immune system by killing abnormal cells, such as cells infected by germs or cancer cells. In some cancers, like acute lymphoblastic leukemia (ALL), cancerous cells become invisible to the T-cells that are meant to kill them. In CAR-T therapy the T-cells are collected and reprogrammed in the lab to recognize and destroy the cancerous cells.

“This type of immunotherapy research is groundbreaking,” said Dr. Natasha Kekre, a hematologist and associate scientist at The Ottawa Hospital, “but it is important to remember that CAR-T therapy is still very new and there can be serious side effects. We need more research to learn about this therapy and make it work for even more people and more kinds of cancer.”

The Ottawa Hospital is one of the first hospitals in Canada to participate in internationally-led CAR-T trials, and as one of Canada’s top research and treatment centres, the hospital is ideally positioned to play a lead role in bringing an innovative CAR-T research program to Canada, and to Canadian patients.

“Our goal is to build Canadian expertise and capacity for innovation in the promising CAR-T field through both laboratory research and clinical trials,” said Dr. Kekre, who is working with a team across the country. “This could lead to better CAR-T therapies that work for more kinds of cancer, as well as innovative approaches for providing CAR-T therapy in the Canadian system.”

Infecting cancer cells with viruses

Another promising biotherapeutic treatment uses oncolytic viruses that selectively infect and kill cancer cells. “Our immune system is constantly trying to recognize and kill cancer cells, but the cancer cells are always trying to hide from it,” explained Dr. John Bell, senior scientist at The Ottawa Hospital. “When you infect a cancer cell with a virus, it raises a big red flag, which helps the immune system recognize and attack the cancer.”

Recent laboratory research from Dr. Bell’s team suggests that a combination of two immunotherapies, oncolytic viruses and checkpoint inhibitors, could be much more successful in treating breast cancer and possibly other cancers.

“We found that when you add a checkpoint inhibitor after the virus, this releases all the alarms and the immune system sends in the full army against the cancer,” said Dr. Bell.

Though these methods have shown promising results, more research and clinical trials are needed.

Cancer-fighting vaccine

In addition to these techniques The Ottawa Hospital’s Dr. Rebecca Auer has found that a cell vaccine, developed in the lab using an individual’s cancer cells combined with a cancer-fighting virus, could be effective in battling cancer. Once injected, this vaccine uses a triple-threat to attack the cancer.

Doctor speaking with a patient in her office at a hospital
Dr. Rebecca Auer, The Ottawa Hospital

First, the virus only infects and kills cancer cells, leaving healthy cells unscathed. Second, the virus produces a protein called interleukin-12, which boosts the immune system’s natural ability to fight the tumour. Third, as a result, the vaccine trains the immune system to recognize and fight off the same kind of tumour if it ever comes back.

Dr. Auer and her colleagues are developing the processes required to manufacture this personalized cell vaccine and plan to initiate a “first in human” clinical trial in 2020.

Lifesaving therapies: from idea to bedside

Today, cancer care is changing at an unprecedented pace. Many patients who, only a few years ago, had few to no treatment options are now being offered hope with treatments that are more targeted and personalized. We are seeing approvals for new cancer drugs grow at an almost exponential rate, while world-class research and clinical trials are being integrated into cutting-edge cancer care.

Over the next 15 years, Canadians will see a 40 percent increase in cancer diagnoses with almost one in two developing cancer in their lifetime. Our ability to translate research into patient therapies coupled with one of the best-equipped cancer centres in the country means we are well-positioned to face this challenge head-on.

Go inside the Biotherapeutics Manufacturing Centre at The Ottawa Hospital.

The Ottawa Hospital is a leading academic health, research, and learning hospital proudly affiliated with the University of Ottawa.

Categories: Biotherapeutics

Excruciating chest pains woke Phyllis Holmes from a deep sleep. A trip to the emergency room revealed a twist in her small intestine. Doctors used an uncommon technique that involved leaving her abdomen clamped open for two days after surgery – it’s the reason Phyllis is alive today.

The first of many miracles

For 18 months Phyllis experienced on-and-off pain in her chest. Some episodes lasted for only a few minutes, while others lasted for several hours. Unable to pinpoint the cause of her pain, Phyllis’ doctor started an elimination process; sending her for various tests, including a visit to the University of Ottawa Heart Institute. When results revealed it wasn’t her heart that was causing such discomfort, doctors ordered a CT scan hoping it would provide some answers.

However, only a few days prior to her scheduled appointment, Phyllis jolted awake in excruciating pain. Lying next to her, concerned, was her husband, Brian Jackson, who insisted they pay a visit to the emergency room. Her pain persisted as they checked in at The Ottawa Hospital’s General Campus. Recognizing the severity of her pain, the admitting staff immediately put her in an examination room.

A life-threatening diagnosis

Dr. Guillaume Martel and Phyllis Holmes embrace at The Ottawa Hospital.
Dr. Guillaume Martel and Phyllis Holmes

After several tests, Phyllis underwent a CT scan. The results showed her life was on the line.

As Phyllis recalls her experience, she describes hearing only one thing – they would need to perform emergency surgery immediately. “That was all I heard,” said Phyllis. “We have to do emergency surgery or you may be faced with a life-threatening circumstance.”

What the CT scan revealed was a small twist in her intestine, causing her entire bowel to turn purple, almost black. “Her whole small intestine was dying,” said Phyllis’ surgeon, Dr. Guillaume Martel, “which is not survivable. But we got to her quickly, and that day, things lined up perfectly.”

Traditionally, with a bowel in such a condition, surgeons would have removed the section of the bowel that was compromised. However, in Phyllis’ case, almost her entire bowel was jeopardized. Removing such a large portion of her bowel would have reduced her to being fed through IV nutrition for the rest of her life.

A mid-surgery decision

Once Phyllis was in the operating room, doctors were able to more accurately assess the severity of the damage caused to her intestine. Some vitality in her bowel remained— an encouraging sign that there was a chance it could be saved. Rather than remove the intestine, they decided to leave her abdomen clamped open and wait.

For two days Phyllis lay sedated in the intensive care unit, her abdomen left open. Throughout that time, Brian recalls the nurses and doctors were attentive and compassionate, letting him know what was going on every step of the way. “I was always in the loop about what was going on,” said Brian, something that he was grateful for during a particularly emotional and stressful time.

“Leaving a patient open can be a form of damage control,” explained Dr. Martel. This technique relieved a lot of pressure in Phyllis’ abdomen, allowing time to see whether her bowel would survive. However, it can be difficult for a doctor to know if this technique will work for one patient over another. Luckily, in Phyllis’ case, it did.

The wait was over

When Phyllis was brought back to the operating room for her second surgery, Dr. Balaa, the surgeon, told Brian what to expect. It could be a long procedure, where they would remove part of her intestine, and in its place attach a colostomy bag. Brian settled in for a long and stressful wait, unsure of what life might be like once Phyllis’ surgery was complete. But less than an hour later, Dr. Balaa appeared with incredible news.

When they took off the covering, a sheet that protected her abdomen while she lay clamped open, her intestine was healthy and back to normal again. To their amazement, her intestine remained viable and all they needed to do was stitch her back up.

Recovery period

The next morning Phyllis woke to Brian’s warm smile at her bedside. While she was unaware of the incredible turn of events, she was grateful to be alive.

She remained at the hospital for a week after the first surgery. While she recovered, Phyllis recalls receiving exceptional care. “The doctors always had so much time for me when they did their rounds,” said Phyllis. “They were very patient and engaged in my situation, it was heartwarming and wonderful.” Phyllis was so grateful, she wanted to show her appreciation.

Showing Gratitude

Dr. Guillaume at The Ottawa Hospital
Dr. Guillaume Martel was part of a team that saved Phyllis’ life.

That’s when Phyllis heard of the Gratitude Award Program. This program was developed as a thoughtful way for patients to say thank you to the caregivers who go above and beyond to provide extraordinary care, every day. It’s a way for patients, like Phyllis, to recognize caregivers by giving a gift in their honour to The Ottawa Hospital. The caregivers are presented with a Gratitude Award pin and a special message from the patient letting them know the special care given did not go unnoticed.

Honouring Dr. Martel and several others through the Gratitude Award Program was a meaningful way for Phyllis to say thank you. “I wanted to be able to give something in return,” said Phyllis.

Dr. Martel was touched by the gesture. “When you receive a pin from a patient like Phyllis, it’s very gratifying,” explained Dr. Martel. “It’s something you can feel good about receiving.”

A healing experience

Phyllis’ journey at The Ottawa Hospital was far more than an emergency room visit and two surgeries. When asked to reflect on her experience, she tells a story of compassionate care and healing, both physically and mentally. “I felt that even though I was there to heal physically, I was getting psychological support as well,” Phyllis explained. “Everyone would use eye contact, or they’d touch my hand with compassion. It was very personal. I saw the divinity in those people,” explained Phyllis. “I saw it. I experienced it first-hand. And it is healing. That is the healing that takes place when you have those very special encounters. It heals you.”

Today, Phyllis feels incredibly grateful for the care she received at The Ottawa Hospital. “It was second to none,” she said.

Dr. Guillaume Martel

In August 2019, Dr. Guillaume Martel was announced as the first Arnie Vered Family Chair in Hepato-Pancreato-Biliary Research. Dr. Martel is a gifted surgeon at The Ottawa Hospital who has saved and prolonged the lives of countless patients, particularly those with cancer. An international search conducted for this Research Chair found the best candidate right here in Ottawa. This Research Chair provides the opportunity for innovative clinical trials and cutting-edge surgical techniques that will benefit our patients for years to come. This was made possible through the generous support of the Vered Family, alongside other donors.

“When Arnie got sick, he needed to travel to Montreal for treatment. It was so hard for him to be away from home and our six children. We wanted to help make it possible for people to receive treatment right here in Ottawa. This Chair is an important part of his legacy.” – Liz Vered, donor

The Ottawa Hospital is a leading academic health, research, and learning hospital proudly affiliated with the University of Ottawa.

Categories: Donors, Gratitude Award, Patient Care

Minimally invasive surgery ‘perfectly’ restores hearing

After a brain tumour began growing in to his ear, Denis Paquette was at risk of losing his hearing in both ears – a circumstance that would strip him of his ability to hear his wife’s voice forever. With traditional brain surgery deemed too risky, Dr. Fahad Alkherayf and Dr. Shaun Kilty were challenged to find a safer solution – removing the tumour through his nose.

A life unlike most

Since birth, Denis Paquette, now 66, has been deaf in one ear. It’s clear he has a deep-rooted understanding of the nuances of having such an impairment. After all, it’s all he’s ever known. Holding the phone to his good ear and turning his head while in conversation to better hear someone are habits he was quick to establish.

But in 2016, these little tricks, which he has cultivated throughout his life, started to fail him. Conversations were getting harder to hear and Denis’ wife, Nicole,

Hospital around the world are looking to The Ottawa Hospital tDr. Fahad AlKherayf and Dr. Shaun Kilty standing in an operating room at The Ottawa Hospital.
Hospitals around the world are looking to The Ottawa Hospital to learn about the type of minimally invasive brain surgery performed by Dr. Fahad Alkherayf (right) and Dr. Shaun Kilty.

noticed that Denis was progressively increasing the volume on the television.

“I was beginning to be frustrated because people were talking to me, but I was just getting parts of the conversation,” said Denis.

Journey to diagnosis

Concerned about his hearing, Denis visited his family doctor. He was sent for various hearing tests, each showing that something was wrong. It was then that Denis was referred to Dr. David Schramm, a hearing specialist at The Ottawa Hospital. Dr. Schramm ordered an MRI that revealed Denis had a rare tumour growing in his skull and in to his inner ear. These weren’t the results Denis and Nicole were expecting.

“I didn’t know what to expect, so it was really shocking news,” said Denis.

Denis needed specialized surgery to remove the tumour and required the expertise of neurosurgeon Dr. Fahad Alkherayf and ear, nose, and throat (ENT) specialist Dr. Shaun Kilty.

Due to the complexity of Denis’ diagnosis, Dr. Alkherayf and his team were challenged to remove the tumour without jeopardizing his hearing completely.

“The tumour was growing in his skull and in to his inner ear, putting pressure on his hearing nerve on the good ear. There was a risk he would lose the rest of his hearing,” said Dr. Alkherayf.

“Despite it being a benign lesion, the impact of it was huge.” – Dr. Fahad Alkherayf

Dr. Alkherayf knew that removing the tumour through Denis’ ear could risk permanently damaging what little hearing he had left. With this in mind, Dr. Alkherayf recommended that Denis undergo the newly-available minimally invasive brain surgery. With this technique, his tumour would be removed through his nostrils instead of through his ear.

The risk was high

Traditionally, brain surgery for a case such as Denis’ would take place through the ear and require a large incision through the skull. But with only one good ear to start with, performing brain surgery in this way could permanently and completely impair his hearing.

Not only could Denis lose his hearing, the traditional method of removing such a tumour has a greater risk of complication, a higher chance of infection, and demands a longer recovery period – up to six months. It would also leave a large scar, beginning in front of his ear and extending all the way up and behind it. The thought of undergoing such a procedure alone was nerve-racking.

A new surgery technique

Over the last several years, Dr. Alkherayf has advanced new techniques for removing various types of brain tumours, known as minimally invasive surgery.

Minimally invasive surgery has transformed the way operations are performed by allowing surgeries to be carried out as keyhole procedures, a surgical procedure that provides access to parts of the body without having to make large incisions. This operation is much safer, with risk of infection and recovery time greatly reduced. In many cases, patients are discharged within just a few days of surgery.

“It’s quicker to recover for patients,” said Dr. Kilty. “Because they don’t have to recover from the extensive dissection that traditional approaches [surgeries] require.”

Performing these types of surgeries requires two physicians – a neurosurgeon to remove the tumour and an ENT to provide access to the tumour through the nose and to control the endoscope. Due to the complex nature of these surgeries, Dr. Alkherayf is among a small group willing to perform them. Many are looking to The Ottawa Hospital to learn about this innovative surgery. “We have become one of the top places in Canada for this technique,” said Dr. Alkherayf.

Denis Paquette sitting outside at a table at The Ottawa Hospital.
Denis Paquette’s hearing was restored after receiving minimally invasive brain surgery at The Ottawa Hospital.

“They did a miracle on me”

On July 20, 2016, Denis underwent a five-hour operation during which Dr. Alkherayf and Dr. Kilty were able to successfully access and remove the tumour through his nose. The insertion of a microscopic tube that would travel from the cavity of where the tumour once was to his sinuses which would prevent future buildup of fluid and prevent the chance of reoccurrence.

When he woke up, Denis was astounded that he could hear his wife’s voice. “I woke up and wow,” said Denis, “I could hear!”

Just two days after his surgery, he was discharged.

“They did a miracle on me. They did something fantastic,” said Denis, whose hearing tests have been perfect ever since.

“They did a miracle on me. They did something fantastic.” – Denis Paquette

Thanks to the care Denis received at The Ottawa Hospital and the benefits of minimally invasive surgery, he can now enjoy watching his television shows and conversing with his wife without issue. He no longer fears a life without sound.

The Ottawa Hospital is a leading academic health, research, and learning hospital proudly affiliated with the University of Ottawa.

Categories: Neuro

OCTOBER 26, 2019 OTTAWA, ON – It was a sold-out night at The Ottawa Hospital Gala, presented by First Avenue Investment Counsel, which recognized three innovative researchers. The elegant ballroom of the Westin Hotel was transformed with exquisite décor and a delectable four-course meal, enjoyed by more than 700 guests. It also marked the final gala with Dr. Jack Kitts as President and CEO of The Ottawa Hospital, who will retire in 2020. Guests paid tribute to Dr. Kitts with a standing ovation for his dedication to providing compassionate and world-class care to the Ottawa community through his leadership since 2002.

The Ottawa Hospital Gala celebrated the transformational work of three researchers dedicated to improving care. Congratulations to this year’s three award winners:

Faizan Khan, recipient of the Worton Researcher in Training Award, recognized for his outstanding work on vein blood clots, including a recent British Medical Journal study establishing long-term risks and consequences of clot recurrence.

Dr. Marjorie Brand, recipient of the Chrétien Researcher of the Year Award, recognized for her groundbreaking discovery of how a blood stem cell decides whether to become a red blood cell or a platelet-forming cell.

Dr. Paul Albert, recipient of the Grimes Research Career Achievement Award, recognized for his leadership in Neuroscience, as well as his innovative work on what causes depression and how to treat it.

The Ottawa Hospital is recognized for its world-leading research that attracts internationally recognized scientists and clinicians from around the world. Tim Kluke, President and CEO of The Ottawa Hospital Foundation, emphasized that it’s corporate and individual philanthropic gifts, which make that a reality. “We are privileged to have the support of a generous community which is helping this city advance research to find new hope for patients now and in the future.”

First Avenue Investment Counsel returned as the presenting sponsor of The Ottawa Hospital Gala this year. Kash Pashootan, CEO and Chief Investment Officer at First Avenue Investment Counsel, said it’s a partnership that aligns perfectly. “Innovative research is a necessary investment in the future of health care in our community and we’re proud to fulfill our duty to The Ottawa Hospital. At First Avenue Investment Counsel, we advise families on all aspects of their financial picture including managing their assets to ensure their secure future for them and future generations. Together, we’re laying the building blocks for the future.”

About The Ottawa Hospital: 

The Ottawa Hospital is one of Canada’s largest learning and research hospitals, with more than 1,200 beds, 12,000 staff members and an annual budget of about approximately $1.3 billion.

The focus on learning and research helps to develop new and innovative ways to treat patients and improve care. As a multi-campus hospital affiliated with the University of Ottawa, specialized care is delivered to the eastern Ontario region and the techniques and research discoveries are adopted around the world. The hospital engages the community at all levels to support our vision for better patient care.

From the compassion of our people to the relentless pursuit of new discoveries, The Ottawa Hospital never stops seeking solutions to the most complex patient-centred care. For more information about The Ottawa Hospital, visit ohfoundation.ca.

Local activist donor pledges $500,000 to take on cancer

Gavin Murphy takes pride in describing himself an activist donor.
Gavin Murphy takes pride in describing himself an activist donor.

Gavin Murphy is unwavering when it comes to his desire to maintain a world-class health care system in our city. He’s unwilling to settle for anything less and he doesn’t think anyone in our community should either. Gavin believes each resident needs to play an active role in giving back, and that’s why this self-described “activist” donor is sharing his story – a story he hopes will lead to a cure for cancer.

This New Edinburgh resident has committed $500,000 to support the Radiation Medicine Program at The Ottawa Hospital – it’s what he wants his lasting legacy to be.

While the Ottawa lawyer isn’t looking for public recognition, he’s not shy about sharing the news of his gift as he hopes it will inspire others to do the same. “Scarce government resources requires those in a position to give significant gifts to step forward and support The Ottawa Hospital.” Gavin adds, “By giving serious thought to my philanthropy, I am hoping to help improve discovery and care for our families, friends, and neighbours.”

Gavin’s interest in cutting-edge research is what enticed him to make this tremendous gift to Radiation Medicine Program with the hope that findings will one day be published. He’s excited about the opportunities which lie ahead and the advancements that will be made.

“I want to give this money while I’m still alive. It’s great that people leave money in their estates, I think that’s wonderful but I want to see the fruits of my labour, in my lifetime.” – Gavin Murphy

It’s the fruits of his labour, which will leave his fingerprints on advancements in cancer care to help others in the future. For Gavin, that’s truly exciting. “I like the idea of funding new, innovative technology. It will leave a lasting legacy and this gift is providing the building blocks for future research in this field.”

Donor support is vital to providing doctors and researchers with state-of-the-art tools. It’s also what allows The Ottawa Hospital to be a trailblazer when it comes to transformational advancements. Dr. Miller MacPherson, the Head of Medical Physics at The Ottawa Hospital says, “It’s the generosity of donors like Gavin which allows The Ottawa Hospital to be innovative with new technologies. This support will provide insight for new discoveries and will have an impact on care through research and technology advancements in the field of cancer research.”
Dr. Jason Pantarotto, Head of Radiation Oncology at The Ottawa Hospital, echoes that sentiment, noting that donations to the Radiation Medicine Program are particularly precious. “Despite radiotherapy being a key treatment for nearly 5,000 cancer patients each year in Ottawa, the amount of research dollars available to improve the science is pretty sparse. We are extremely grateful to donors, such as Gavin, who see the benefits of investing in the team and equipment that exists here at The Ottawa Hospital.”

For Gavin, his ultimate goal is to help find a cure for cancer.

“This gift will provide a foundation to greater understanding of cancer and I hope it will help obliterate cancer sometime down the road.”- Gavin Murphy

The reality is The Ottawa Hospital will touch each person in our community in some way. For Gavin, that’s a good reason for not only himself but also for others to step forward. “If people want to be well looked after in a world-class system, we have to ensure a world-class system is maintained.”

The way Gavin sees it, we’ll all need The Ottawa Hospital at some point, and there’s a way for each person in our community to support it. “You need people who are in the position to give, and those who can give smaller amounts, in greater numbers to support the hospital equally.”

Download Pulse podcast to hear Gavin’s message to the community about why future support is critically important.

The Ottawa Hospital is a leading academic health, research, and learning hospital proudly affiliated with the University of Ottawa.

Categories: Cancer, Innovation and Technology, Innovation and Technology, Innovation and Technology, Innovation and Technology, Technology, Technology

SEPTEMBER 25, 2019, OTTAWA, ON – September resulted in $2.21 million donated to The Ottawa Hospital as a direct result of community support – solidifying our city’s dedication to ensuring world-class care and research in eastern Ontario. Events including THE RIDE, powered by Mattamy Homes, the President’s Breakfast, golf tournaments, and community-inspired events, all contributed to this excellent example of dedication local residents have to The Ottawa Hospital.

The funds will directly support patient care and research at The Ottawa Hospital. Tim Kluke, President and CEO of The Ottawa Hospital Foundation, said this is a perfect example of a community rallying to ensure doctors, researchers and nurses have the right tools to care for their patients. “Philanthropy takes many forms, and each of these special events embodies the important role The Ottawa Hospital plays in our city. We are grateful for all of the support and we never take it for granted,” said Kluke.

In many cases, community leaders stepped forward to support The Ottawa Hospital and called on their friends and colleagues to do the same. This was the case for Cyril Leeder and Janet McKeage who co-chaired the annual President’s Breakfast held earlier this month.

“Beyond the right tools and equipment, research is fundamental to the advancements in care we are seeing. It’s research which is allowing The Ottawa Hospital to be one of the best health-care centres in the country and it is the generosity of our community which makes that possible,” said Leeder.

McKeage echoed that sentiment, “Together, we have the capability to help push the boundaries when it comes to health care in our city.”

It is community support, which provides critical funds to help purchase equipment not funded by our tax dollars and helps fund the work of a researcher who has dedicated his or her life to finding a cure.

About The Ottawa Hospital:

The Ottawa Hospital is one of Canada’s largest learning and research hospitals, with more than 1,200 beds, 12,000 staff members and an annual budget of about approximately $1.3 billion.

The focus on learning and research helps to develop new and innovative ways to treat patients and improve care. As a multi-campus hospital affiliated with the University of Ottawa, specialized care is delivered to the eastern Ontario region and the techniques and research discoveries are adopted around the world. The hospital engages the community at all levels to support our vision for better patient care.

From the compassion of our people to the relentless pursuit of new discoveries, The Ottawa Hospital never stops seeking solutions to the most complex patient-centred care. For more information about The Ottawa Hospital, visit ohfoundation.ca.

30 years after treatment, leukemia survivor forever grateful

The importance of cancer research is not lost on Robert Noseworthy. He’s reminded of it every time he looks in the mirror.

Robert is a cancer survivor and not a day goes by that he doesn’t appreciate each moment he’s had to share with his two children, who are now adults.

On October 21, 1988, Robert was diagnosed with acute lymphoblastic leukemia—a childhood leukemia. He was living in Montreal at the time with his young family, including Julianne who was 18 months old and his infant son, David.

A grim prognosis

“I was given a 13% chance of survival with 6 months to live. My doctor said it was very unusual for a 30-year-old to have a childhood leukemia,” says Robert.

And so, the cancer journey began for this father of two. It would include numerous rounds of chemotherapy and radiation treatments, which put him into remission, but the journey didn’t end there. “In March 1989, I received a bone marrow transplant from my sister, who was a six-on-six match.”

Thanks to that match, Robert beat the odds. He gives full credit to cancer research as the reason he is alive today. It’s what has driven Robert and his family to become dedicated supporters of cancer research at The Ottawa Hospital. “That is my why. I do my small part and to raise funds for cancer research,” he says.

Robert Noseworthy with his daughter Julianne after they cycled 109 kms during THE RIDE on September 8, 2019.
Robert Noseworthy with his daughter Julianne after they cycled 109 kms during THE RIDE on September 8, 2019.

Time to give back

Giving back has been important to Robert. Each year, his family comes together to cycle and raise funds through THE RIDE, a cycling fundraiser. It’s also been important to him to instill that in his children as they grew up. “I received all this help but now it’s time to give back.”

For Julianne, giving back as a family to The Ottawa Hospital and advancing research has become just as important to her.

“If it wasn’t for cancer research and everything my dad had been through, we wouldn’t be the family that we are today,” says Julianne.

Glancing over at her father, with a smile, Julianne says, “My why is you.”

The way Robert sees it; he is alive because of the investment of others who came before him and he wants to be that hope for someone else battle cancer. “60 years ago someone invested in cancer research. 30 later, I was the beneficiary of that generosity and that’s why I’m here today.”

The Ottawa Hospital is a leading academic health, research, and learning hospital proudly affiliated with the University of Ottawa.

Categories: Cancer, Cancer, Cancer, Cancer, Donors, Donors

A melanoma diagnosis

The Ottawa Hospital, The Ottawa Hospital Foundation, Ian McDonell
Ian McDonell received immunotherapy in 2017, which erased any trace of his melanoma.

Several years ago, Ian McDonell, a Staff Sergeant with the Ottawa Police and father of three had just lost his father to cancer and his brother was dying of melanoma. Ian’s wife insisted he see his physician to check out a mole on his back. It turned out to be an ulcerated nodular malignant melanoma – an aggressive form of skin cancer.

Ian had surgery to remove it along with a lymph node from his left groin. Several weeks later, he had a lymph node removed from his armpit. Following these surgeries, he had no signs of cancer, but due to his family’s history, Ian was at high risk for relapse.

Sobering news

Ian was feeling well, but during a standard monitoring visit in June 2017, his CT and MRI scans showed sobering news. He had half a dozen tumours in his groin and abdomen, and three more tumours metastasized to his brain. Ian’s cancer was stage 4.

Given the severity of the findings, Dr. Michel Ong at The Ottawa Hospital suggested an aggressive approach – a recently approved immunotherapy treatment.

Unmasking cancer

Scientists have tried for decades to stimulate the immune system to attack cancer cells. But the game changer was the discovery that cancer cells make key molecules, called immune checkpoint proteins, that suppress immune cells and prevent them from attacking the cancer. These immune checkpoint proteins cloak the cancer from the immune system. New drugs called immune checkpoint inhibitors remove this cloak and allow immune cells called T-cells to naturally attack and destroy the cancer.

“The idea of chemotherapy is to kill off cancer directly,” said Dr. Ong. “There are potential side effects, because chemotherapy tries to poison the cancer.

“Immunotherapy does not directly affect the cancer itself. Instead, immunotherapy unmasks the cancer to your immune system by flipping some switches on T-cells, and the body’s own immune system does the rest.” – Dr. Michael Ong

Ian McDonell with his wife Michelle (left), and their daughters Kendra, Macy, and Ainsley, hiking in the Adirondack Mountains in 2019.
Ian McDonell with his wife Michelle (left), and their daughters, hiking in the Adirondack Mountains in 2019.

CyberKnife treatment

Ian started on a combination of two immunotherapies given intravenously in the chemotherapy unit at The Ottawa Hospital’s Cancer Centre. He also underwent CyberKnife radiotherapy treatment where high doses of radiation were directed at his brain tumours. He bravely continued with the second round of immunotherapy, but was so sick, he had to be taken off the treatment and started on steroid medications to slow down the immune system. Ian felt better, but his immunotherapy was on hold.

Shrinking tumours

When Ian began to develop weakness in his face, he worried his cancer was getting worse. It wasn’t. Scans showed one tumour had shrunk from 25 to 10 mm, and another had shrunk from eight to four mm.

Dr. Ong recommended trying a single immunotherapy rather than two, and while the treatment made Ian very sick, it did the trick.

Two months later, the results of a PET scan, MRI, and a CT scan showed that he was tumour-free. All trace of his cancer was gone.

Oncologist Dr. Michael Ong said recent immunotherapies are hugely successful for treating melanoma.
Oncologist Dr. Michael Ong said recent immunotherapies are hugely successful for treating melanoma.

Advances in immunotherapy

When Dr. Ong first met Ian in 2013, options for immunotherapy or targeted chemotherapy weren’t available. Thanks to incredible advances in immunotherapy, there is now hope.

“In the last few years, we’ve gone from having very poor options to having many effective options for melanoma. That’s because cancer therapy continues to develop at a very rapid pace,” said Dr. Ong. “We, at The Ottawa Hospital, are constantly participating in practice-changing clinical trials. The standard of care is constantly changing, as it should. We are continually trying to push the limits of cancer treatment.”

The Ottawa Hospital is a leader in cancer immunotherapy research, both in terms of developing new therapies and in offering experimental treatments to patients. Currently, there are approximately 70 active cancer immunotherapy clinical trials being conducted at the hospital involving nearly 700 patients. The hospital also hosts a national network for immunotherapy research and has developed a number of unique immunotherapies made directly of cells and viruses.

Hope for the future

Because of successful immunotherapy treatments, patients like Ian are now planning a future of living cancer-free.

“When the provincial exams for police services came up, I said, ‘I’m gonna write it, because I’ve got a bit of hope now.’” said Ian.

More importantly, in addition to his career plans, immunotherapy has allowed Ian to plan for the future with his family and a chance to watch his daughters grow up.

Hear more about oncologist Dr. Michael Ong’s work with immunotherapy.

The Ottawa Hospital is a leading academic health, research, and learning hospital proudly affiliated with the University of Ottawa.

Categories: Clinical Trials, Immunotherapy
To support life-saving research at The Ottawa Hospital that helps patients like Ian, please donate.
Donate

More Inspiring Stories

Staying on tempo: Cutting-edge surgery technique helps musician get back on her feet
When painful leg ulcers threatened Mina King’s mobility and ability to play the piano with ease, experts at The Ottawa Hospital came together in perfect unison with cutting-edge surgery techniques and compassionate care.
Patient Care, World-Leading Research
New approach to treating brain tumours changed young patient’s life
After nearly a decade of mini seizures, Stefanie Scrivens was diagnosed with grade 2 oligodendroglioma at only 20 years old. She would be one of the first to benefit from a new treatment option to increase her chance of survival, including two complex, 8-hour awake surgeries at The Ottawa Hospital to remove the rare tumour from her brain.
Cancer, Neuro
COVID-19 at The Ottawa Hospital: a year of relentless care and research
A community that rallied to support our hospital, the race to find answers to a relentless virus, and the story of three nurses caring for COVID-19 patients during unprecedented times.
COVID-19, Biotherapeutics, Donors, Gratitude Award, Patient Care, World-Leading Research
Sign up to receive updates on the transformational care taking place right here at our hospital, inspiring patient stories, and the latest research discoveries impacting healthcare for you, your loved ones, and our community.